Background. Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C 24 ).
first-line therapy. Ritonavir-boosted protease inhibitor (PI)-containing therapy has been associated with the development of dyslipidemia and insulin resistance that may predispose to cardiovascular and cerebrovascular injuries [1] [2] [3] . On the contrary, raltegravir, an integrase strand inhibitor, has been shown to have milder lipid and metabolic effects relative to PI-based or nonnucleoside reverse transcriptase inhibitor-based therapy, producing minimal changes in plasma lipid levels, insulin resistance, or alteration of body habitus [4] [5] [6] .
Furthermore, the extent of lipid and other metabolic changes in ritonavir-boosted PI regimens may vary by regimen type and by systemic ritonavir exposure [7] . Ritonavir is both a substrate and an inhibitor of the cytochrome P450 (CYP) 3A isoenzyme and, to a lesser extent, CYP2D6 [8] . All PIs vary in their affinity and impact on CYP3A4 isoenzyme [9] . As higher ritonavir exposure has been correlated with greater elevation in plasma lipids and the occurrence of other metabolic side effects [10, 11] , the differential effect of coadministered PI on ritonavir plasma concentrations could impact the lipid profile of a given ritonavir-boosted PI regimen.
The AIDS Clinical Trials Group (ACTG) Study A5257 evaluated the virologic efficacy and tolerability of tenofovir disoproxil fumarate (TDF)/emtricitabine in combination with ritonavirboosted atazanavir, raltegravir, or ritonavir-boosted darunavir in treatment-naive human immunodeficiency virus (HIV)-infected adults in the United States and Puerto Rico [12] . In the current report, we examined the lipid and other metabolic effects of these 3 antiretroviral regimens, with the aim of evaluating differences between the 2 PI arms, and between each of the PI arms and the raltegravir arm. Additionally, in the 2 PI arms of the study, the effects of atazanavir and darunavir on plasma trough ritonavir concentrations (C 24 ) and the association between plasma ritonavir C 24 and fasting lipid measures were evaluated.
METHODS

Study Population and Design
ACTG A5257 was a phase 3, randomized, open-label trial in which participants were randomly assigned 1:1:1 to receive 1 of 3 regimens-(1) 300 mg of atazanavir (Reyataz, BristolMyers Squibb) plus 100 mg of ritonavir (Norvir, Abbott Laboratories) once daily (ritonavir-boosted atazanavir); (2) 400 mg of raltegravir (Isentress, Merck Inc) twice daily; or (3) 800 mg of darunavir (Prezista, Janssen Therapeutics) plus 100 mg of ritonavir once daily (ritonavir-boosted darunavir)-each with the fixed-dose combination of 300 mg of TDF plus 200 mg of emtricitabine (Truvada, Gilead Sciences). This study was approved by the biomedical investigational research committee at each site, and all participants gave written informed consent before study enrollment (ClinicalTrials.gov identifier NCT00811954).
The study population included ART-naive, HIV-1-infected adults with plasma HIV-1 RNA level >1000 copies/mL. Study evaluations were completed before entry; at entry; at weeks 4, 8, 16, 24 , and 32; and every 16 weeks thereafter. Participants were followed, regardless of meeting an endpoint, for 96 weeks after enrollment of the last participant. The primary objective of ACTG A5257 was to determine regimen equivalence with regard to virologic efficacy and tolerability over 96 weeks. Study A5257 had two important metabolic objectives. The first was to compare the impact of the study regimens on a variety of metabolic measures including fasting plasma lipid and glucose levels, prevalence of metabolic syndrome, and anthropometric measures. The study also aimed to detect an association between plasma ritonavir C 24 at steady state and 48-week changes in fasting plasma lipid levels in the two ritonavir-boosted PI arms.
Fasting plasma lipid measurements evaluated included total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), calculated non-HDL-C (calculated as TC -HDL-C), and calculated low-density lipoprotein cholesterol (LDL-C) (calculated as TC -[HDL-C + (TG/5)], if TG ≤400 mg/dL). Per protocol, these parameters were assessed at weeks 0, 24, 48, 96, and 144. Fasting was defined as nothing to eat or drink for at least 8 hours except for water or decaffeinated black coffee, and required prescription medications. Fasting lipid profile levels were performed at any Clinical Laboratory Improvement Amendments-compliant laboratory. Steady-state plasma ritonavir concentrations were evaluated by ritonavir C 24 assessed once at least two weeks after initiation of ritonavirboosted atazanavir or ritonavir-boosted darunavir and obtained within 22-26 hours after the last self-reported dose of ritonavir. Sampling for ritonavir C 24 continued until a target sample size of 258 participants with evaluable steady-state ritonavir C 24 measures was reached. Concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described [13] at the University of California, San Francisco, on batched plasma samples. Incident metabolic syndrome was assessed based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III criteria [14, 15] .
Statistical Analysis
Unless otherwise specified, all analyses included all eligible participants with fasting lipid measures available at study entry but otherwise followed the intention-to-treat principle; as-treated analysis including participants who completed the study on randomized treatment and sensitivity analyses excluding participants on lipid-lowering medications ( primarily aimed at reducing TC, TG, and LDL) and antihypertensive agents were also performed. Missing data were considered missing completely at random. Mean changes in fasting plasma lipid measures over time were estimated with 95% confidence intervals (CIs). Pairwise treatment differences at weeks 24, 48, 96, and 144 were estimated with 97.5% CIs and compared between the treatment arms using pairwise Student t tests. The cumulative probability of developing metabolic syndrome over time was estimated by Kaplan-Meier method. Participants not meeting criteria for metabolic syndrome prior to end of follow-up were censored at the time of their last visit requiring metabolic evaluation; participants meeting criteria for metabolic syndrome at study entry were excluded from this analysis. All treatment group comparisons were assessed at a 2.5% level of statistical significance to provide modest control of the type I error in the setting of multiple comparisons.
Ritonavir C 24 was analyzed on the natural logarithm scales and compared by treatment arms using Wilcoxon rank-sum tests. Associations between ritonavir C 24 and change from baseline in levels of fasting TG, non-HDL-C, and calculated LDL-C at week 48 and week 96 were analyzed using linear regression; treatment-dependent associations were evaluated via 2-degrees of freedom tests for different intercept and slope. For analyses of these pharmacokinetic objectives, lipid values obtained following discontinuation of ritonavir-boosted PI or initiation of lipid-lowering agents were excluded, with values imputed with the last observations obtained prior to these events. The target sample size of 258 participants randomized to each of the ritonavir-boosted PI arms provided 90% power to detect an association between ritonavir C 24 and 48-week change in fasting TG, equating to a 32 mg/dL lower change in fasting TG over 48 weeks per 12.6 ng/mL lower ritonavir C 24 , and allowed for a 20% loss due to missing data ( providing effective sample size of 103 participants per ritonavir-boosted PI arm).
RESULTS
A total of 1809 evaluable participants were enrolled from 57 sites into A5257 between 22 May 2009 and 9 June 2011. Of these, 1797 with confirmed baseline fasting samples and clinical measures were included in the current analyses. Baseline demographics, metabolic and lipid measures, and clinical characteristics of the study population were well balanced between treatment arms ( Table 1) . The study population comprised 24% of women, 34% of non-Hispanic white, 42% of nonHispanic black, and 21% of Hispanic. Full demographic details have been previously presented [9] .
Eighty-eight percent of participants had the NCEP target TC <200 mg/dL, 75% had TG <150 mg/dL, 89% had non-HDL-C <160 mg/dL, and 89% (of 1170 with TG ≤400 mg/dL) had calculated LDL <130 mg/dL, whereas only 43% had HDL-C ≥40 mg/dL. Median (Q1, Q3) fasting blood glucose level was 84 (78, 92) mg/dL; 89% had fasting blood glucose levels <100 mg/dL. Twenty-one percent of participants had evidence of metabolic syndrome at study entry. Fifty-eight percent of participants reported a history of smoking, 38% reported a smoking history >10 years, and 39% were current smokers. At study entry, 106 (6%) were taking lipid-lowering agents, 273 (15%) were taking antihypertensive agents, and 64 (4%) were on hypoglycemic therapy at study entry (Table 1) .
Changes from baseline and absolute values over time in lipid measures and other metabolic outcomes following therapy are summarized in Figure 1 , Supplementary Figure 1 , and Table 2 , respectively. In pairwise comparisons, there were no differences in the mean change from baseline to all study weeks (24, 48 , and 96) in any of the lipid measures between the ritonavirboosted atazanavir and the ritonavir-boosted darunavir arms (all P > .05). However, each of the ritonavir-boosted PI arms had greater increases relative to the raltegravir arm in TC, TG, non-HDL-C, and LDL-C (all P ≤ .001). HDL-C increased modestly in all 3 arms (an average increase of 6 mg/dL over 96 weeks), with no significant differences in mean change from baseline to all study weeks evaluated between treatment arms (all P > .06) ( Figure 1A-C, Supplementary Figure 1A) . From baseline to week 96, the percentage of participants who had taken lipidlowering agents increased from 5% to 11% in the ritonavir-boosted atazanavir arm, 6%-9% in the raltegravir arm, and 6%-14% in the ritonavir-boosted darunavir arm. Sensitivity analyses of changes in lipid measures over time by treatment arms that included as-treated analyses with participants who completed the study on their original randomized treatment, or limited to participants not taking lipid-lowering agents, yielded findings that were consistent with the intention-to-treat analyses.
Fasting plasma glucose, waist circumference, and waist-toheight ratio increased following ART initiation in all 3 treatment arms (Figure 1D and 1E; Supplementary Figure 1B) . In pairwise comparisons, larger increases in waist circumference were observed with the raltegravir arm compared with the ritonavir-boosted darunavir arm at weeks 48 and 96 (all P ≤ .023) but not compared with the ritonavir-boosted atazanavir arm (P ≥ .07); no other treatment group differences were apparent. The cumulative probability of incident of metabolic syndrome by week 96 was 21% (95% CI, 18%-26%) for the ritonavir-boosted atazanavir arm, 22% (95% CI, 18%-26%) for the raltegravir arm, and 22% (95% CI, 19%-27%) for the ritonavir-boosted darunavir arm, with no apparent difference between the treatment arms (all P ≥ .7; Figure 2 ).
Of the 230 participants who had plasma obtained for evaluation of drug concentrations, 109 in the ritonavir-boosted atazanavir arm and 121 in the ritonavir-boosted darunavir arm had evaluable steady-state ritonavir C 24 . Median (Q1, Q3) ritonavir C 24 was 69 (40-105) ng/mL in the ritonavir-boosted atazanavir arm, and 74 (38-110) ng/mL in the ritonavir-boosted darunavir arm, with no apparent difference between the arms (P = .89). Associations between ritonavir C 24 and changes in fasting plasma lipid measures were not apparent (P ≥ .4) at either week 48 or week 96. While treatment group specific estimates of associations between ritonavir C 24 and lipid change were in opposite directions (negative in the atazanavir group, positive in the darunavir group; Supplementary Figure 2) , none of these associations were statistically significant (P > .09), and no evidence of PI-specific associations was apparent (P ≥ .09) ( Table 3) .
DISCUSSION
In this prospective, randomized, open-label study evaluating raltegravir and the two ritonavir-boosted PI regimens as initial treatment of HIV infection, we identified differences in lipid changes Abbreviations: ATV/r, ritonavir-boosted atazanavir; BMI, body mass index; DRV/r, ritonavir-boosted darunavir; HDL-C, high-density liproprotein cholesterol; HIV-1, human immunodeficiency virus type 1; LDL, low-density liproprotein cholesterol; RAL, raltegravir; SD, standard deviation; TC, total cholesterol; TG, triglycerides. a Calculated as [fasting calculated LDL-C (mg/dL) = fasting TC -fasting HDL-C -(fasting TG/5)], only for subjects with fasting TG ≤400 mg/dL; subjects with fasting TG >400 mg/dL were excluded. and anthropometric changes between treatment regimens. As expected based on prior small studies, we found increases in fasting lipid measures including TC, TG, non-HDL-C, and LDL-C following therapy with the two ritonavir-boosted PI arms but not with the raltegravir arm. These lipid changes were similar at every study evaluation point between the two ritonavir-boosted PI arms, confirming previously reported equivalence in the lipid effects of these two widely used PI regimens in clinical practice [16] . Of note, the mean HDL-C level was low in the majority of participants at entry, as expected for ART-naive subjects [17] . However, small increases were observed for this lipid measure in all 3 arms with no apparent differences between arms, also consistent with prior data suggesting that initiation of ART modestly improves HDL-C levels [17] . Metabolic syndrome is a term that describes a cluster of clinical, anthropometric, and laboratory measures that confer heightened risk of cardiovascular disease and type 2 diabetes [18] . There is a relatively high prevalence of metabolic disorders among HIV-infected individuals [19] , which has been attributed to lipid abnormalities, particularly high plasma TG and low HDL-C commonly seen in untreated HIV disease [20] , and to antiretroviral-induced metabolic and body shape changes [21, 22] . At baseline, the fasting lipid profile was below NCEP lipid thresholds for individuals with one or more cardiovascular risk factors for a large proportion of participants, fasting blood glucose levels were <100 mg/dL in 89%, and the use of hypoglycemic agents was modest. The presence of pretherapy metabolic syndrome was high (21%), and similar to that previously reported for HIV-infected individuals [23, 24] . In contrast to the general population, among whom metabolic syndrome is primarily driven by hypertension, hyperglycemia, and abdominal obesity [25] , baseline metabolic syndrome in this study was driven largely by a combination of low plasma HDL-C levels and hypertriglyceridemia-two lipid parameters directly affected by HIV infection [17] . Abbreviations: ATV/r, ritonavir-boosted atazanavir; CI, confidence interval; DRV/r, ritonavir-boosted darunavir; HDL-C, high-density lipoprotein cholesterol; LDL, lowdensity liproprotein cholesterol; RAL, raltegravir.
During the study, the cumulative probability of developing new metabolic syndrome was high (approximately 22% at 96 weeks). However, contrary to expectation due to the known effects of ritonavir-boosted PI regimens on lipids, no differences between the study arms were apparent. The greater increase in waist circumference observed with the raltegravir-based therapy counterbalanced the contribution of higher TG levels in the PI arms, accounting for the comparable cumulative probability of metabolic syndrome in all three treatment arms. This notwithstanding, the high rate of metabolic syndrome at baseline and following ART in this population should raise some concern, as individuals with metabolic syndrome are susceptible to a Figure 2 . Cumulative probability of metabolic syndrome, by treatment group. A total of 1363 subjects were included in this analysis; 381 subjects who had metabolic syndrome at baseline and 53 subjects who were censored at baseline were excluded. Abbreviations: ATV/RTV, ritonavir-boosted atazanavir; DRV/RTV, ritonavir-boosted darunavir; RAL, raltegravir. Test for PI-specific association (2 df) P = .53 P = .35 P = .22
Estimates (mg/dL) are from simple linear regression analysis of RTV C 24 on change from baseline to the given week for each lipid parameter. RTV C 24 values (on the natural log scale) were centered on the group mean for modeling, so the intercept estimate represents the average lipid change from baseline for an average (geometric mean) RTV C 24 of approximately 55 ng/mL. The test for a PI-specific association is a 2-df F test for nonzero treatment group main (intercept) and interaction (RTV C 24 × treatment) coefficients.
Abbreviations: C 24 , plasma trough concentration; CI, confidence interval; df, degrees of freedom; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PI, protease inhibitor; RTV, ritonavir; TG, triglycerides. a Estimate represents the estimated difference in the lipid change from baseline to given week for each 1-log (natural) difference in RTV C 24 ; note that 1 log is approximately the difference between the first and third quartiles of observed RTV C 24 in the A5257 study.
variety of conditions including cardiovascular diseases, type 2 diabetes, certain malignancies, polycystic ovarian syndrome, and reactive airway disease [26] [27] [28] .
The lipid changes experienced with ritonavir-boosted PI therapy are speculated to be driven to a larger extent by the ritonavir component of the regimens. In the TMC114-C159 trial [29] , ritonavir-boosted atazanavir increased the plasma exposure of ritonavir, whereas ritonavir-boosted darunavir had an opposite effect. That healthy volunteer study with only 28 days' duration could not evaluate the metabolic consequences of this differential ritonavir systemic exposure. The present study provided an opportunity to rigorously evaluate this question. Steady-state ritonavir trough concentrations in our study population were comparable to previous reports for the tablet formulation [30] , and were not different between the ritonavir-boosted atazanavir and darunavir regimens. Associations between ritonavir exposure and lipid changes over 48 and 96 weeks were also not apparent (both overall and within specific PI regimens). Several reasons may account for the differences between our findings and the TMC114-C159 trial, including the larger size of our study population, which may have limited the confounding effect of intrasubject variability in drug concentrations; the use of HIVinfected rather than healthy volunteers; and the longer study follow-up time points at which lipid sampling was performed in the current study. It should also be noted that it is possible that ritonavir exposure may affect other metabolic outcomes other than plasma lipids, although the scant published literature to date does not support an association between ritonavir concentration and changes in anthropometric measurements [31] .
The diversity of the study population with relatively high proportions of women and participants of ethnic minority backgrounds, which closely mirrors the demography of the HIV/ AIDS epidemic in many parts of the United States, makes these findings of the current analyses generalizable to clinical practice. Furthermore, the pharmacokinetic/pharmacodynamic analysis included a robust sample of >200 ritonavir C 24 samples collected within a specific time interval. This robust sample size is large enough to militate against the confounding effect of intrasubject variability in plasma antiretroviral concentrations that have limited the interpretation of previous smaller studies. In addition, this study captured data from baseline to week 144, allowing a longer assessment of changes in metabolic measures relative to other studies. Self-reported adherence to ART and nonobservance of ritonavir administration prior to pharmacokinetic sampling limits nearly all studies of this type. Fasting plasma lipid fractions were limited only to TC, TG, non-HDL-C, LDL-C, and HDL-C. Typically, dual-energy X-ray absorptiometry (DEXA) data are used to assess changes in body fat composition with therapy. However, DEXA scans were not obtained in the general study participants, but were obtained on a subset of participants and will be reported separately.
In this large, randomized prospective trial, raltegravir produced the most favorable lipid profile compared with 2 ritonavir-boosted PIs. Metabolic syndrome rates at baseline were high, and the cumulative probability of developing new metabolic syndrome post-ART was similar across all arms. Ritonavir C 24 was not different between the 2 ritonavir-boosted PIs arms, and had no relationship with the modest but similar increases in plasma lipids observed with either the ritonavir-boosted atazanavir-based or ritonavir-boosted darunavir-based regimen. The long-term clinical significance of the lipid changes noted with the two ritonavir-boosted PI regimens relative to the raltegravir-based regimen deserves further evaluation, particularly when initiating ART in patients with high cardiovascular risk profiles.
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